15 results about "Formoterol" patented technology

The invention belongs to the field of pharmaceutics, and particularly relates to a composition containing budesonide and formoterol, and the composition provided by the invention is in a specific pH range, adopts a specific surfactant addition mode, also adopts moist heat sterilization, and is free of toxic and side effects. The prepared inhalation suspension of formoterol and budesonide has better delivery rate and total delivery amount, better fine particle fraction and smaller particle size distribution, has the advantages of low temperature, short time, strong penetrating power, economy, rapidness and the like compared with dry heat sterilization and moist heat sterilization, and is more suitable for industrial mass production.

The present invention provides methods of treating anemia in a patient in need thereof, comprising administering to the patient in need thereof an effective amount of formoterol or a pharmaceutically acceptable salt thereof (e.g., formoterol fumarate or arformoterol tartrate). The formoterol or a pharmaceutically acceptable salt thereof (e.g., formoterol fumarate or arformoterol tartrate) may be administered conjointly with an erythropoiesis-stimulating agent, optionally wherein the anemia is refractory to the erythropoiesis-stimulating agent. The present invention further provides methods of promoting differentiation of an erythroid progenitor cell toward a mature red blood cell in a patient in need thereof, comprising administering an effective amount of formoterol or a pharmaceutically acceptable salt thereof (e.g., formoterol fumarate or arformoterol tartrate). The formoterol or a pharmaceutically acceptable salt thereof (e.g., formoterol fumarate or arformoterol tartrate) may be administered conjointly with other FDA- approved drugs such as luspatercept, lenalidomide, erythropoiesis-stimulating agents (ESAs), including but not limited to epoetin alfa or darbepoetin alfa, and / or a hypomethylating agent, such as azacitidine and / or decitabine.

The invention generally refers to a stainless steel can for use in a metered dose inhaler device, containing an aerosol formulation, comprising glycopyrronium bromide and formoterol, or a salt or a solvate thereof, optionally in combination with one or more additional active ingredient, endowed with a high stability.

The present invention relates to a dry powder composition for an inhalation formulation comprising formoterol or a pharmaceutically acceptable salt thereof, a tiotropium bromide anhydride and a pharmaceutically acceptable carrier. The synthesis methods of the formoterol and the tiotropium bromide are respectively realized through specific chemical reaction steps, and finally high-purity active ingredients are obtained. The weight ratio of the active ingredients to the carrier in the composition is 1: (1-15): (50-50000), and the carrier can be selected from lactose, cane sugar, mannitol or amino acid and the like. The preparation method comprises the following steps: micronizing, mixing, filling into hollow capsules, and finally preparing a finished product through aluminum-plastic packaging. The composition disclosed by the invention has good chemical stability and high inhalation efficiency, can be kept for more than two years at normal temperature, and is accurately and uniformly administered in a targeted lung through a dry powder inhalation device, so that formoterol and tiotropium bromide synergistically play a role in relaxing bronchial smooth muscles, and clinical requirements are met.

The present invention relates to salts of budesonide 21-phosphate with β2 adrenergic agonists, preferably with formoterol, pharmaceutical compositions containing the same and the use thereof in the treatment of respiratory inflammatory pathologies, obstructive pathologies and allergen-induced airway dysfunctions. The invention further relates to the process for preparing said salts.

The invention belongs to the technical field of organic chemical synthesis, and provides a synthesis method of (R, R)-formoterol, which comprises the following steps: mixing N-[2-(4-methoxyphenyl)-1-methyl ethyl] benzylamine and ethyl acetate, adding S-mandelic acid for resolution, and carrying out alkaline hydrolysis on the obtained crystal and a sodium hydroxide solution to obtain an intermediate 1; mixing the intermediate 1 and R-4-benzyloxy-3-nitrophenyl ethylene oxide, and coupling to obtain an intermediate 2; mixing the intermediate 2, activated iron powder, methanol, chloroform and hydrochloric acid for reaction to obtain an intermediate 3; mixing the intermediate 3, trichloromethane, acetic anhydride and formic acid, and carrying out formylation reaction to obtain an intermediate 4; and mixing the intermediate 4, a palladium carbon catalyst and methanol, and carrying out deprotection to obtain the (R, R)-formoterol. The designed route is easy to operate, and the technical defects of a racemization method and a chiral control method in the prior art are overcome.

The invention discloses a pharmaceutical composition for preventing or treating asthma diseases, the pharmaceutical composition comprises a bronchiectasis agent and glucocorticoid, the bronchiectasis agent is preferably formoterol and pharmaceutically acceptable salts thereof or solvates thereof or solvates of the salts, and the glucocorticoid is preferably fluticasone furoate. The pharmaceutical composition provided by the invention can more safely and effectively delay the next attack time of an acute asthma patient.

The invention generally refers to a stainless steel can for use in a metered dose inhaler device, containing an aerosol formulation, comprising glycopyrronium bromide and formoterol, or a salt or a solvate thereof, optionally in combination with one or more additional active ingredient, endowed with a high stability.

The present invention relates to salts of budesonide 21-phosphate with β2 adrenergic agonists, preferably with formoterol, pharmaceutical compositions containing the same and the use thereof in the treatment of respiratory inflammatory pathologies, obstructive pathologies and allergen-induced airway dysfunctions. The invention further relates to the process for preparing said salts.

The present invention relates to a transdermal composition comprising a compound selected from the group comprising formoterol, salbutamol, salmeterol, fenoterol, mixtures thereof or salts thereof, and dimethylsulfoxide. The present invention further relates to a composition comprising a compound selected from the group comprising salbutamol, clenbuterol or salts thereof, and comprising at least one of water or a monohydric alcohol.

The present invention relates to salts of budesonide 21-phosphate with a beta2 adrenaline agonist, and preferably with formoterol, pharmaceutical compositions comprising the same and their use in the treatment of respiratory tract inflammatory diseases, obstructive diseases and allergen-induced airway dysfunction. The invention also relates to a method for preparing said salt.

The invention belongs to the technical field of inhalation powder aerosols, and particularly discloses a preparation method of an inhalation particle composition with the bulk density of 0.26-0.28 g / ml. The composition comprises budesonide, formoterol fumarate dihydrate and lactose monohydrate, and the mass median diameter is 1t; the mass ratio of the raw materials is (80-160): 4.5: (3835.5-3915.5). The preparation method comprises the steps of high-shear mixing, high-humidity regulation, gravity compaction and two times of rolling agglomeration, and the bulk density is precisely regulated and controlled by controlling the compaction pressure (0.2-0.35 Mpa) and the agglomeration time (1-5 minutes). The problems that in the prior art, the degradation rate of active ingredients is high (impurities are larger than or equal to 1.2%), the process is complex (six steps), and the fluidity is poor (the repose angle is 45 degrees) are solved, the process steps are remarkably simplified, the impurities are reduced to be smaller than or equal to 0.5%, and the fluidity (the repose angle is smaller than or equal to 34 degrees) and the dose division precision (RSDlt; the device is suitable for a multi-dose reservoir type device such as Turbuhaler and the like, and is used for treating asthma and chronic obstructive pulmonary diseases.

The present invention generally relates to an aerosol formulation comprising formoterol and beclomethasone dipropionate, said formulation being contained in a coated can, particularly useful for the use in a pressurised metered dose inhaler for the teratment of respiratory diseases.

The present invention generally relates to an aerosol formulation comprising formoterol, beclomethasone dipropionate and glycopyrronium bromide, said formulation being contained in a coated can, particularly useful for the use in a pressurised metered dose inhaler for the treatment of respiratory diseases.

A pharmaceutical composition comprises a drug component. The drug component is a combination of one pharmaceutically acceptable salt of glycopyrrolate, beclomethasone dipropionate, and one long acting beta-2-agonist (LABA) selected from formoterol and pharmaceutically acceptable salts thereof. The pharmaceutical composition also comprises a propellant component. The propellant component is at least 90 weight percent 1,1-difluoroethane (HFA-152a). The pharmaceutical composition is in the form of a solution and optionally comprises ethanol, but is free of other polar solvents / co-solvents. The drug component is the sole drug component in the pharmaceutical composition.